Constipation Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility
The purpose of this study is to determine whether prucalopride is safe and effective in the
treatment of constipation in elderly subjects living in a nursing facility.
Hypothesis:
Prucalopride up to a dose of 4 mg once daily is safe and well tolerated in in elderly
subjects living in a nursing facility.
This is a multicenter, Phase II, dose-escalation trial with a 4 week double-blind,
placebo-controlled treatment period. There will be four treatment cohorts (0.5 mg, 1 mg, 2
mg, or 4 mg) with 25 subjects in each. The first cohort of 25 subjects will be randomly
assigned to receive either 0.5 mg R108512 or placebo in a 4 to 1 ratio, respectively, for
four weeks. After two weeks of treatment, the safety and tolerability of this dose will be
evaluated for each subject by an independent (external) safety committee. If, at the
completion of treatment, the safety committee grants approval to proceed to a higher dose,
the second cohort will be randomly assigned to receive either 1 mg R108512 or placebo for
four weeks. In a likewise manner, each dose will be evaluated for safety and tolerability
before the next cohort will be treated with a higher dose. No subject can participate in
more than one treatment cohort.
Subjects will be instructed not to change their diet or lifestyle during the trial. Subjects
will be allowed to continue the use of routine stool softeners and fiber supplements during
the trial; however, all existing stimulant or osmotic laxative medication will be withdrawn.
If, during the trial, the subject does not have a complete bowel movement for three or more
consecutive days, he/she will be allowed the use of his/her usual stimulant or osmotic
laxative or an enema as a rescue medication. No laxatives or enemas should be used within
the 24 hours before and 24 hours after the start of double-blind treatment.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |